01 December 2007
In vitro investigation of MRP 2 in the cyclosporine A – pravastatin interplay
R.l Kato, M. Nishide, C. Kodzu, Y. Ijiri, K. TanakaAnn Transplant 2008; 13(1): 34-34 :: ID: 880190
Abstract
Background: Cyclosporine A (CsA) has been used to treat a variety of autoimmune diseases. It is reported that CsA is metabolized by CYP3A and excreted via P-glycoprotein and multidrug resistant protein (MRP) 2 in humans. Pravastatin has been used to treat hyperlipidemia, and it is reported that pravastatin is excreted via MRP2 in humans. We had two cases where the blood CsA level was increased following pravastatin administration. It is suggested that CsA interacted with pravastatin via MRP2. In this study, we investigated the effects of pravastatin on CsA transport via MRP2.
Material/Methods: Caco 2 cells were seeded on Transwell® at a density of 105 cells/well. Calcein, a substrate of MRP, was put into Caco 2 cells, and CsA (5, 50 μM) and pravastatin (0.1, 1.0 mM) were added to the apical and basolateral sides (n = 6). After a 30 min incubation, calcein was effl uxed from Caco 2 cells, and the calcein level of the culture medium was assayed. CsA was put into Caco 2 cells, and pravastatin (0.1, 1.0 mM) was added to the apical and basolateral sides (n=3). After 1 hour of incubation, CsA was effluxed from Caco 2 cells and the CsA level of the culture medium was assayed.
Results: The calcein effl ux to the apical side was decreased significantly by the addition of pravastatin (1.0 mM) and CsA (5, 50 μM), respectively. The CsA efflux to the apical side was decreased significantly by the addition of pravastatin (1.0 mM).
Conclusions: The results demonstrate that CsA transport may
be inhibited competitively by pravastatin via MRP2.
Keywords: Cyclosporine, hyperlipidemia, Medullary Thyroid Cancer
In Press
04 Aug 2022 : Original article
Long-Term Patency of All-in-One Sleeve Patch Graft Venoplasty in 16 Patients Who Underwent Living Donor Liv...Ann Transplant In Press; DOI: 10.12659/AOT.936888
22 Jul 2022 : Original article
Diagnostic Role of Tumor Markers for Hepatocellular Carcinoma in Liver Transplantation Candidates: An Analy...Ann Transplant In Press; DOI: 10.12659/AOT.936937
22 Jul 2022 : Original article
Development of a Novel Model for Predicting Postoperative Short-Term Outcome in Patients with Hepatitis B-R...Ann Transplant In Press; DOI: 10.12659/AOT.936732
22 Jul 2022 : Original article
Leucine-Rich Alpha-2-Glycoprotein (LRG-1) as a Potential Kidney Injury Marker in Kidney Transplant RecipientsAnn Transplant In Press; DOI: 10.12659/AOT.936751
Most Viewed Current Articles
26 Jan 2022 : Review article
Recurrence of Hepatocellular Carcinoma After Liver Transplantation: Risk Factors and Predictive ModelsDOI :10.12659/AOT.934924
Ann Transplant 2022; 27:e934924
29 Dec 2021 : Original article
Efficacy and Safety of Tacrolimus-Based Maintenance Regimens in De Novo Kidney Transplant Recipients: A Sys...DOI :10.12659/AOT.933588
Ann Transplant 2021; 26:e933588
24 Jul 2020 : Review article
Kidney Transplantation in the Times of COVID-19 – A Literature ReviewDOI :10.12659/AOT.925755
Ann Transplant 2020; 25:e925755
15 Mar 2022 : Case report
Combined Liver, Pancreas-Duodenum, and Kidney Transplantation for Patients with Hepatitis B Cirrhosis, Urem...DOI :10.12659/AOT.935860
Ann Transplant 2022; 27:e935860